What Amorphical does

Amorphical is a privately held Israeli biotechnology company founded in 2004 and headquartered in Ness Ziona, Israel. It develops therapeutics based on a proprietary nano-amorphous calcium carbonate (ACC) platform technology inspired by the blue crayfish's ability to store calcium in amorphous (non-crystalline) form for rapid exoskeleton regeneration. The disordered, nanometric mineral structure (10-100 nm particle size) provides approximately double the fractional calcium absorption of crystalline calcium carbonate (22.1% vs 13.7%) and dissolves preferentially in acidic microenvironments, enabling targeted delivery to sites of inflammation, tumor acidity, and metabolic dysfunction while sparing healthy tissue. The company has built a portfolio of nearly 200 patent applications (more than 130 granted) and a 3,200 sq.m. GMP/ISO/HACCP-certified production facility in the Arava Desert.

Amorphical operates four clinical-stage therapeutic programs: AMOR-1 (Phase 2 under FDA IND for hypoparathyroidism, 81 participants, demonstrating 50% dose reduction), AMOR-18 (Phase 1/2 for moderate-to-severe COVID-19 showing 0% ICU transfers/deaths vs 23% placebo), an enteric-coated ACC program for moderate-to-severe Crohn's disease (Phase 2 with 62.5% sustained remission at 48 weeks), and a Phase 2 trial for Stage IV pancreatic cancer launched at Shaare Zedek Medical Center in November 2025. In parallel, the company sells ACC-based calcium supplements directly to consumers as a higher-bioavailability alternative to conventional calcium products.

The business model combines long-term pharmaceutical development — targeting FDA-regulated approvals and potential licensing/royalty economics in bone/metabolic disease, inflammatory disease, and oncology — with a smaller near-term commercial supplements revenue stream. Clinical work is conducted exclusively through partnerships with leading Israeli medical centers, and the company has assembled a leadership team with pharmaceutical veterans from Teva (Copaxone development) and SRI International. No revenue, funding total, or commercial scale figures are publicly disclosed.

Name

Amorphical

Legal name

Amorphical Ltd.

Website

https://amorphical.com

Company type

Private

Founded year

2004

Operating status

Operating

Short description

Amorphical is an Israeli clinical-stage biotechnology company developing nano-amorphous calcium carbonate (ACC) therapeutics for hypoparathyroidism, Crohn's disease, pancreatic cancer, and COVID-19, and selling ACC-based calcium supplements directly to consumers, supported by nearly 200 patents and a GMP-certified production facility.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Mineral Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Ground or Treated Mineral and Earth Manufacturing (327992)

SIC

Pharmaceutical Preparations (2834), Industrial Inorganic Chemicals (2810)

akta.pro primary industry

Minerals & Trace Elements (Calcium, Magnesium, Zinc, Iron; Chelated Minerals) (AFAJAKAB)

akta.pro secondary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

Keywords

• Amorphous calcium carbonate
• Biopharmaceutical therapeutics
• Mineral-based medicine
• Calcium supplements
• Clinical stage drugs

Headquarters

HQ city

Ness Ziona

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. ACC-based calcium supplements: Commercial sale of amorphous calcium carbonate supplements for bone health, positioning as superior alternative to conventional calcium supplements for consumers seeking enhanced bioavailability
2. Pharmaceutical development: Development and potential future commercialization of nano-amorphous mineral therapeutics for inflammatory diseases, metabolic disorders, and oncology through FDA-regulated clinical pathways
3. Oncology adjunct therapy: Stage IV pancreatic cancer Phase 2 clinical trial evaluating nano-amorphous mineral therapy as adjunct to standard chemotherapy, with data expected Q3 2026

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Amorphical develops and manufactures proprietary nano-amorphous calcium carbonate (ACC)-based therapeutics and supplements derived from biomimicry of the blue crayfish gastrolith. The company sells commercial ACC calcium supplements for bone health (B2C) and advances a clinical-stage pipeline of therapeutic candidates targeting hypoparathyroidism (AMOR-1, Phase 2), Crohn's disease, Stage IV pancreatic cancer, and previously COVID-19 (AMOR-18), with multiple delivery formulations including oral, inhaled, enteric-coated, and topical.

Product overview

Amorphical operates as a biotechnology company offering a proprietary nano-amorphous mineral platform technology centered on Amorphous Calcium Carbonate (ACC). The company's portfolio includes therapeutic products (AMOR-18 for COVID-19, AMOR-1 for hypoparathyroidism, and investigational therapies for pancreatic cancer, Crohn's disease) along with consumer calcium supplements. The ACC platform delivers highly bioavailable minerals that respond to acidic microenvironments, making it applicable across bone and metabolic disorders, inflammatory diseases, and oncology. The technology is inspired by the blue crayfish's ability to rapidly build exoskeletons using amorphous calcium carbonate.

Differentiator

Problem solved

Functional benefit

Products and services

• Amorphous Calcium Carbonate (ACC) Platform
• ACC Calcium Supplements
• AMOR-18 (COVID-19 Therapeutic)
• AMOR-1 (Hypoparathyroidism Therapy)
• Nano-Amorphous Mineral Therapy for Stage IV Pancreatic Cancer

Quantifiable outcome

• 62.5% sustained clinical remission at 48 weeks in Crohn's disease Phase 2 trial
• +3 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Shaare Zedek Medical CentercoreStrategic or Co-development Partner · 24 November 2025Single-center clinical partnership for Stage IV pancreatic cancer Phase 2 trial led by Principal Investigator Dr. Offer Porim, evaluating nano-amorphous carbonate therapy as adjunct to standard of care with enrollment of 10 participants and follow-up for up to 12 months
• Rambam Medical Center - Bone and Mineral Metabolism UnitcoreStrategic or Co-development PartnerClinical study (AMCS009) conducted by the Bone and Mineral Metabolism Unit evaluating ACC in patients with chronic primary hypoparathyroidism, demonstrating stable calcium control with 50% reduction in elemental calcium dose
• Israeli Medical Centers (Ziv, Shamir, Kaplan)coreStrategic or Co-development PartnerMulticenter Phase 1/2 clinical trial for COVID-19 (AMOR-18) conducted across three Israeli medical centers during Delta and early Omicron waves, demonstrating zero ICU transfers or deaths in treatment arm

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Entera Bio: Clinical-stage biotech developing oral delivery of therapeutics for bone and metabolic diseases, including hypoparathyroidism and osteoporosis. Most directly comparable given shared focus on novel oral delivery for underserved bone/parathyroid indications.
• Bone Therapeutics: Clinical-stage biotech developing bone cell therapy and regenerative solutions for orthopedic conditions and bone diseases. Comparable platform approach to addressing bone and metabolic disorders with novel mineral/biologic delivery.
• Keros Therapeutics: Clinical-stage biotech developing novel therapeutics targeting TGF-beta superfamily for blood and bone disorders. Comparable as similarly-sized clinical biotech platform company pursuing first-in-class mechanisms across bone and hematologic indications.

Broad incumbents

• Ascendis Pharma: Established rare-disease biotech with TransCon PTH (palopegteriparatide) for hypoparathyroidism directly competing with Amorphical's AMOR-1. Larger, well-funded competitor with completed Phase 3 data and BLA filing in the same indication.
• Radius Health: Bone health-focused biopharma with Tymlos (abaloparatide) for osteoporosis. Comparable in targeting bone and metabolic diseases with novel mineral/peptide therapeutics.
• Ultragenyx Pharmaceutical: Rare disease biotech with established hypoparathyroidism franchise (Crysvita/burosumab for XLH) and broader mineral metabolism focus. Comparable in targeting rare endocrine bone disorders with novel mineral pathway therapeutics.
• Amgen: Global biopharma with Prolia/Xgeva (denosumab) for osteoporosis and bone metastases. Represents the incumbent competitive benchmark in bone therapeutics that Amorphical's bone/metabolic pipeline must differentiate against.

Emerging players

• Mesoblast: Cell therapy biotech with remestemcel-L for inflammatory diseases including potential Crohn's applications. Comparable in pursuing non-immunosuppressive approaches to inflammatory conditions where Amorphical positions ACC.
• Tarsus Pharmaceuticals: Late-stage clinical biotech with novel therapeutic platform approach across multiple indications. Comparable as similarly-sized platform biotech pursuing first-in-class mechanisms across diverse disease areas.

Others

• Bio-Techne: Life sciences tools and clinical diagnostics company with bone metabolism research reagents. Adjacent connection through shared expertise in calcium signaling, mineral metabolism research tools, and bone health biomarkers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amorphical

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amorphical